Natera Inc. Common Stock (NTRA)
Stock · NASDAQ · Health Care
$393.33as of 10/16/2026
Price chart
Active signals
NTRA Signal Track Record
How signals performed across all stocks →What NTRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +3.5% | 64% | September 15, 2026 |
| Bollinger Band Breakout | 29 | +1.9% | 66% | September 15, 2026 |
| Bollinger Band Breakdown | 19 | +7.9% | 79% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +5.7% | 71% | May 22, 2026 |
| Any 20-session window (baseline) | +3.3% | 63% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profili…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 6,135
- Website
- www.natera.com/
Fundamentals
- 1-day range
- $384.23$408.82
- Market cap
- $38.01B
- P/E (trailing)
- —
- P/E (forward)
- -1757.21
- EPS (trailing)
- $-1.37
- Dividend yield
- —
- Beta
- 1.54
- Avg. volume
- 1.45M
How Natera Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
22 analyst ratings
Natera Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NTRANatera Inc. Common Stock$393.44▼ 2.80%Market cap $38.01BP/E —$170.82$437.41
- HUMHumana Inc. Common Stock$413.16▼ 4.41%Market cap $44.10BP/E 39.25$163.11$456.5
- CNCCentene Corporation Common Stock$69.16▼ 1.91%Market cap $31.71BP/E —$31.63$70.37
- ILMNIllumina Inc. Common Stock$262.54▼ 2.01%Market cap $29.25BP/E 48.62$88$309.35
- DGXQuest Diagnostics Incorporated Common Stock$235▼ 1.74%Market cap $26.32BP/E 24.67$171.18$248.84
- LHLabcorp Holdings Inc. Common Stock$317.95▼ 2.19%Market cap $25.96BP/E 25.55$244.52$341.8
- GHGuardant Health Inc. Common Stock$158.6▼ 4.39%Market cap $21.15BP/E —$61$191.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NTRA Natera Inc. Common Stock | $38.01B | — | $393.44 | ▼ 2.80% | $170.82$437.41 |
| HUM Humana Inc. Common Stock | $44.10B | 39.25 | $413.16 | ▼ 4.41% | $163.11$456.5 |
| CNC Centene Corporation Common Stock | $31.71B | — | $69.16 | ▼ 1.91% | $31.63$70.37 |
| ILMN Illumina Inc. Common Stock | $29.25B | 48.62 | $262.54 | ▼ 2.01% | $88$309.35 |
| DGX Quest Diagnostics Incorporated Common Stock | $26.32B | 24.67 | $235 | ▼ 1.74% | $171.18$248.84 |
| LH Labcorp Holdings Inc. Common Stock | $25.96B | 25.55 | $317.95 | ▼ 2.19% | $244.52$341.8 |
| GH Guardant Health Inc. Common Stock | $21.15B | — | $158.6 | ▼ 4.39% | $61$191.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $435benzinga · 10/13/2026
- How FDA Breakthrough Status For Natera’s Multi‑Cancer Test (NTRA) Has Changed Its Investment StoryYahoo · 10/10/2026
- Natera (NTRA) Stock May Be 33% Below Fair Value Despite FDA Breakthrough NewsYahoo · 10/10/2026
- Natera (NTRA) Could Be 33% Undervalued Following FDA Breakthrough Device DesignationYahoo · 10/10/2026
- Why Natera (NTRA) Stock Is Up TodayYahoo · 10/10/2026
- Could You Have Seen The Run In Tempus AI Stock Coming?Yahoo · 10/9/2026
- Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood TestYahoo · 10/9/2026
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection AssayYahoo · 10/9/2026
- Natera Receives FDA's Breakthrough Device Designation For Its Multi-Cancer Early Detection AssayBenzinga · 10/9/2026
Insider Activity
Insider Actions →- Matthew Rabinowitz · October 7, 2026 · Gift6.0K
- Solomon Moshkevich · October 1, 2026 · Sale1.8K @ $415.07
- Solomon Moshkevich · October 1, 2026 · Sale954 @ $413.11
- Solomon Moshkevich · October 1, 2026 · Sale200 @ $411.62
- Steven Leonard Chapman · October 1, 2026 · Sale1.3K @ $413.31
- Jonathan Sheena · September 23, 2026 · Sale220 @ $390.53
- Jonathan Sheena · September 23, 2026 · Sale1.9K @ $389.71
- Jonathan Sheena · September 23, 2026 · Sale1.3K @ $388.76
- Jonathan Sheena · September 23, 2026 · Sale2.8K @ $387.74
- Jonathan Sheena · September 23, 2026 · Sale2.3K @ $386.64
- Jonathan Sheena · September 23, 2026 · Sale390 @ $385.29
- Jonathan Sheena · September 23, 2026 · Sale110 @ $390.42
- Jonathan Sheena · September 23, 2026 · Sale2.3K @ $389.69
- Jonathan Sheena · September 23, 2026 · Sale1.3K @ $388.71
- Jonathan Sheena · September 23, 2026 · Sale2.7K @ $387.65
Institutional Ownership
March 31, 2026
- Total shares held
- 114.39M
- Total value held
- $19.05B
- Institutional holders
- 751
- Unknown12.18M
- Unknown10.68M
- Unknown6.01M
- Unknown4.77M
- Unknown3.42M
- Unknown3.21M
- Unknown3.06M
- Unknown2.78M
- Unknown2.55M
- Unknown2.54M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Natera Named to TIME Best Inventions, Gets PT Hikes
Natera's Signatera test was named to TIME's Best Inventions of 2026, highlighting its clinical relevance. The company also announced a collaboration with TransCode Therapeutics for a colorectal cancer trial. Morgan Stanley and TD Cowen recently raised their price targets, reflecting strong analyst confidence in the stock's trajectory.
Natera Named to TIME Best Inventions, Gets PT Hikes. Natera's Signatera test was named to TIME's Best Inventions of 2026, highlighting its clinical relevance. The company also announced a collaboration with TransCode Therapeutics for a colorectal cancer trial. Morgan Stanley and TD Cowen recently raised their price targets, reflecting strong analyst confidence in the stock's trajectory.